The event kicks off at 1 pm EDT on Thursday, September 10.
This is an online variant of the popular conference format Proactive has run for more than a decade and enables communication between investors and management from some of the world's cutting-edge businesses.
Heat Biologics, a clinical-stage biopharmaceutical, is developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine.
Thursday’s presentation follows some promising preclinical results from a study of a potential vaccine based on its already-developed gp96 platform.
A study found that Heat’s vaccine candidate “significantly increases the frequency of systemic and tissue-specific CD8+ T-cells by conferring cellular immunity that‘s essential against any viral infection, including SARS-CoV-2”, the virus that causes the COVID disease.
It elicits a robust immune response directed against the Spike protein of SARS-CoV-2.
"We believe that these results are a powerful reinforcement that this platform represents a unique and relevant paradigm for novel vaccine development, capable of inducing cellular immune responses in epithelial tissues such as the lungs,” said Jeff Wolf chief executive.